Mesoblast ( (MESO) ) has provided an announcement.
On April 14, 2025, Mesoblast Limited, a company involved in the biotechnology sector, announced several updates regarding its securities with the Australian Securities Exchange. The company reported the cessation of 30,000 unquoted equity securities due to unmet conditions, effective March 31, 2025. This announcement also included updates on the issuance and conversion of other securities, reflecting changes in the company’s capital structure.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast faces substantial financial challenges with consistent losses and negative cash flows. Technical analysis indicates bearish momentum, compounded by a negative P/E ratio. However, recent FDA approval and fundraising efforts provide a glimmer of hope, as highlighted in the earnings call. Overall, the stock score reflects the need for significant strategic improvements to enhance financial stability and growth potential.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
YTD Price Performance: -50.80%
Average Trading Volume: 323,133
Technical Sentiment Signal: Buy
Current Market Cap: $1.26B
See more insights into MESO stock on TipRanks’ Stock Analysis page.